摘要
胃是原发性胃肠道淋巴瘤(PGL)最常见的发生部位,以非霍奇金淋巴瘤中的弥漫大B细胞淋巴瘤(DLBCL)为主。在临床表现、免疫表型及分子遗传学等方面具有高度异质性,与其他良恶性肿瘤难以区分。近年来其发病率也呈现明显上升趋势。虽然治疗方法在过去十几年发生了显著变化,但是仍没有形成统一的治疗模式。现将对胃DLBCL规范化治疗方案及最新治疗研究进行阐述,以期待为患者带来更好的治疗方案。
The stomach is the most common site of primary gastrointestinal lymphoma(PGIL),with diffuse large B-cell lymphoma(DLBCL)being the main type of non-Hodgkin's lymphoma.It has high heterogeneity in clinical manifestations,immunophenotype,and molecular genetics,and is difficult to differentiate from other benign and malignant tumours.The incidence of primary gastric DLBCL has shown the significant upward trend in recent years.Although therapeutic approaches for this disease have been continuously innovated and improved in the past decade,there is still no uniform treatment model.This article elaborates on the standardized treatment schemes and the latest treatment research of gastric DLBCL,in order to bring better treatment schemes for patients.
作者
王贞
吴元玉
连树林
WANG Zhen;WU Yuanyu;LIAN Shulin(Changchun University of Chinese Medicine,Changchun 130117,China;Department of Gastrointestinal Colorectal Surgery,China-Japan Union Hospital,Jilin University,Changchun 130033,China;Department of General Surgery,the Affiliated Hospital of Changchun University of Chinese Medicine,Changchun 130021,China)
出处
《长春中医药大学学报》
2024年第3期345-349,共5页
Journal of Changchun University of Chinese Medicine
基金
吉林大学科技项目校内子项目(3D518C333430)。
作者简介
王贞(1995—),女,硕士研究生,主要从事普通外科学方面研究;通信作者:吴元玉,男,主治医师,电子信箱-624680268@qq.com;连树林,男,主任医师,硕士研究生导师,电子信箱-lianshulin@163.com。
